Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Nitro Games expects revenue increase and a positive result for Q4 / 2023

As a result of continued revenue increase and careful cost control, the company expects a profitable fourth quarter of 2023, with a positive cash flow. Nitro Games Oyj’s key figures in the fourth quarter of 2023 according to preliminary and unaudited calculations are the following (comparison figures from the previous year in parenthesis): Q4/2023 · Revenues increased to approximately EUR 2.9 million (EUR 2.3 million) · EBITDA increased to approximately EUR 0.7 million (EUR -0.4 million) · EBIT increased to approximately EUR 0.3 million (EUR -0.6 million) · Net result

Nordnet: Monthly statistics December

In December, Nordnet’s customers made 3,832,700 trades in listed financial instruments, which corresponds to 203,900 trades per day. The number of new customers in December amounted to 12,900 and the number of new customers in 2023 is 155,000. The total number of customers at the end of December was 1,862,900. Net savings for December was SEK 3.5 billion and the total net savings during 2023 is SEK 34.7 billion. The savings capital was SEK 825 billion and lending amounted to SEK 29.5 billion at the end of December. +-----------------+---------+---------+---------+---------+--------+|

Alex Therapeutics Reports Positive Results from the Randomized-Controlled Trial of its Digital Therapy for Anxiety

●        AlmeeTM, developed by Alex Therapeutics in partnership with Vicore Pharma, is a mobile app that offers personalized treatment for anxiety based on cognitive behavioral therapy (CBT) ●        The pivotal trial demonstrated significantly reduced levels of anxiety and improved quality of life for people living with pulmonary fibrosis, a chronic and fatal disease   Stockholm, January 4, 2024 – Alex Therapeutics and Vicore Pharma today announced positive results of the COMPANION study, investigating the efficacy of Almee, a 9-week digital cognitive behavioral therapy (CBT)

Repurchase of Outokumpu’s own shares

Outokumpu OyjStock exchange releaseJanuary 4, 2024 at 9.30 am EETRepurchase of Outokumpu’s own shares On January 3, 2024, Outokumpu has completed repurchases of its own shares as follows (ISIN FI0009002422): +-------+----------------+------------------------------------+----------------+|Trading|Number of shares|Weighted average price / share, EUR*|Total cost, EUR*||venue | | | |+-------+----------------+------------------------------------+----------------+|CEUX |111,303 |4.2089

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir’s licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has dosed the first patient with TNG348, a novel USP1 inhibitor. Tango received U.S. Food and Drug Administration clearance on its Investigational New Drug application for TNG348 in September 2023.   TNG348 is a novel USP1 (ubiquitin-specific protease 1) inhibitor for the treatment of BRCA1/2-mutant and other homologous

TF Bank AB (publ): Invitation to the presentation of the Year-end report 2023

TF Bank AB will publish its Year-end report for 2023 on Friday 19 January 2024 at 07.00 CET. We welcome media, institutional investors, analysts and other interested parties to participate in a conference call at 08.15 CET.  Agenda (CET)  07.00 – Year-end report published  08.15 – Conference call with CEO Joakim Jansson and CFO Mikael Meomuttel who will present the Year-end report. It will be possible to ask questions after the presentation.  To follow the conference call online go to www.tfbankgroup.com. To participate in the conference call, please click on the Zoom link below

NYAB Oyj - Managers' Transactions

NYAB PlcMANAGERS' TRANSACTIONS04 January 2024 at 09:30NYAB Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: PM Ruukki OyPosition: Closely associated person(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Markku KankaalaPosition: Member of the BoardIssuer: NYAB OyjLEI: 743700UX7WTIOT3QO547Notification type: INITIAL NOTIFICATIONReference number: 48545/5/5 ____________________________________________Transaction date: 2023-12-27Outside a trading venue

Agreement with the IT distributor N.O.D is increased by 75 million DKK

Company Announcement no. 1-24Copenhagen, January 4, 2024 In reference to company announcement no. 28-23, Shape Robotics and Network One Distribution are extending the framework agreement by an additional minimum of €10 million (approx. MDKK 75) to be delivered in 2024. The framework agreement encompasses a broad spectrum of Shape Robotics solutions, including proprietary products and third-party offerings, primarily for public acquisitions in Component C 15: Education of PNRR, which includes "SmartLabs. Today's news does not alter the guidance announced for 2024, where Shape

Metso to deliver four FIT Crushing Stations in the Americas

Metso Corporation’s press release on January 4, 2024, at 09:00 a.m. EETMetso will supply four FIT™ Crushing Stations in the Americas. Three of the crushing stations will be delivered to an iron ore mine in Brazil and one to a gold plant in Canada. The combined value of the orders is approximately EUR 20 million. The Brazilian orders are booked in Metso’s Minerals segment 2023 fourth-quarter order intake.  The game-changing crushing and screening solution was launched in 2020. Since then, Metso has sold 24 FIT™ Stations around the world for applications ranging from gold, iron ore,

Transaction in Own Shares

    04 January 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |03/01/2024|+-----------------------------------------------------------

Cereno Scientific submits request to the FDA for “compassionate use” of CS1 for treatment of patients with rare disease Pulmonary Arterial Hypertension (PAH)

Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that the company has submitted a request to the FDA for Expanded Access, sometimes called “compassionate use”, to investigational drug CS1 for use in an extension of the ongoing Phase II trial evaluating CS1 in PAH. The initiative is prompted by a request from an investigator in the ongoing Phase II study. Cereno has submitted a request to the FDA under the ‘Expanded Access to Investigational Drugs for Treatment Use’ for expanded access to CS1,

Paul Smith signs with Ingrid

Paul Smith, Britain’s leading independent design company, partners with the delivery experience platform Ingrid to optimize their global delivery operations and cover all stages of the customer journey with a strong personal touch. Founded as a small shop in Nottingham in 1970, Paul Smith has grown into a global brand sold on six continents. It has flourished from menswear design into a lifestyle company for everyone, known for its distinctive signature multi-coloured stripes. “You can find inspiration in everything,” Sir Paul Smith says. Paul Smith clothes are

UNION therapeutics announces enrollment of the first patient in the UCORIS Phase 2 IIT study of orismilast in patients with ulcerative colitis

· UCORIS is an investigator-initiated, Phase 2 study of orismilast for the treatment of moderate to severe ulcerative colitis (UC) · UC is a chronic, inflammatory bowel disease with substantial unmet medical need for new oral treatments · Orismilast is a next-generation, high potency PDE4 B/D selective inhibitor with recently reported positive Phase 2b results in psoriasis and Phase 2 results in hidradenitis suppurativa (HS); orismilast also recently completed enrollment in an ongoing Phase 2b study in atopic dermatitis   Hellerup, Denmark, January 4, 2024 – UNION therapeutics A/

Invitation to presentation of EQT AB’s Year-end Report 2023

EQT AB’s Year-end Report 2023 will be published on Thursday 18 January 2024 at approximately 07:00 CET. EQT will host a conference call at 08:30 CET to present the report, followed by a Q&A session.The presentation and a video link for the webcast will be available here  from the time of the publication of the Year-end Report. To participate by phone and ask questions during the Q&A, please register here  in advance. Upon registration, you will receive your personal dial-in

More lives can be saved if ambulance staff receive AI-support

Assessing how seriously injured a person is, involves weighing up lots of different parameters fast. If healthcare professionals could get support making fast-paced, life-critical decisions from an AI tool, more lives could be saved. This is shown by research from Chalmers University of Technology in Sweden, along with the University of Gothenburg and the University of Borås. "If severely injured people are transported directly to a university hospital, the chances of survival increase, as there are resources to take care of all types of injuries. Therefore, we need to be able

Salmon Evolution ASA: Q4 2023 Operational update

Salmon Evolution ASA ("Salmon Evolution" or the "Company", OSE: SALME) ends 2023 with an all-time high biomass and record harvest volumes in Q4. As per 31 December 2023 the Company had a standing biomass of more than 2,200 tonnes (LW) and had all-time high net biomass production of 1,439 tonnes (LW) in the quarter. The Company continues to see strong biological performance with good appetite and low mortality at Indre Harøy. Salmon Evolution harvested a record high 1,104  tonnes (HOG) in the fourth quarter, with a 90 % superior share and tight weight concentration. Harvest volumes in

NRC Group ASA - Appointed to a major civil contract in Norway - NOK 625 million

Forsvarsbygg has appointed NRC Norge AS, a company wholly owned by NRC Group ASA, to a contract for ground, foundation and construction work in connection with a new quay at Haakonsvern Naval Base. The contract is valued at approximately NOK 625 million and is the largest civil contract to date for NRC Norge. The work will commence in February 2024 and is scheduled for completion in June 2027. Closing date for submission of complaints is 10 days from today, and formal contractual signing can take place after this period at the earliest. For further information, please contact:

Successful launch of Ovzon 3

Ovzons proprietary developed satellite Ovzon 3 has now successfully been launched from SpaceX Cape Canaveral launch site in Florida, USA. Ovzon 3 will enter into service by mid-year 2024, when it has reached its orbital position.Ovzon 3 is a revolutionary geostationary communications satellite. It is the first in its class of communications satellites that has been specifically designed and developed to provide the highest degree of performance, mobility and resiliency – offering superior performance for all mission critical assignments. "We are immensely proud of the fact that Ovzon 3

BAKKAFROST: Share Savings Plan Transaction

As a part of the share savings plan for employees in 2023, the following primary insiders have purchased Bakkafrost shares: · Regin Jacobsen, CEO, purchased 31 shares. After the transaction, he holds directly and indirectly 4,640,281 shares. · Høgni Dahl Jakobsen, CFO, purchased 22 shares. After the transaction, he holds directly and indirectly 76,636 shares. · Odd Eliasen, Managing Director, purchased 21 shares. After the transaction, he holds 186,712 shares. · Annika Frederiksberg, Board Member, purchased 9 shares. After the transaction, she holds directly and indirectly 16,

Joint WSC, BIMCO and ICS statement on joint international statement on Red Sea attacks

Washington/Copenhagen/London, 3 January 2024; The World Shipping Council, the International Chamber of Shipping and BIMCO today expressed their thanks to the 12 nations that have jointly condemned the ongoing illegal attacks on ships in the Red Sea and unlawful detention of vessels and crews there.As the governments of the United States, Australia, Bahrain, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, New Zealand, and the United Kingdom have all stated, these attacks are unacceptable, illegal and directly threaten the freedom of navigation that is fundamental to global

Nordea Bank Abp: Repurchase of own shares on 03.01.2024

Nordea Bank AbpStock exchange release – Changes in company’s own shares03.01.2024 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 03.01.2024 completed repurchases of own shares (ISIN: FI4000297767) as follows: +----------+-------+-------------------+-------------------+| Trading |Number | Weighted average |Total cost, EUR* **||venue (MIC| of |price / share, EUR*| || Code) |shares | ** | |+----------+-------+-------------------+-------------------+|XHEL |155,879|11.28 |1,757,629.

Symrise has purchased an additional 8,344,367 shares in Swedencare at up to SEK 64.00 – will compensate those who accepted the mandatory public offer

Press release3 January 2024 On 5 June 2023, Symrise AG (“Symrise”) announced a mandatory public offer to the shareholders of Swedencare AB (publ) (“Swedencare”) at SEK 37.50 per share (the “Offer”). The acceptance period for the Offer commenced on 21 June 2023 and expired on 26 July 2023. As announced on 28 July 2023, the Offer was accepted by shareholders with a total of 270,521 shares in Swedencare, corresponding to a total of 0.17 percent of the share capital and votes in Swedencare. In accordance with previously published press releases, Symrise has acquired a total of 8,891,018

Transaction in Own Shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 03 January 2024 REDDE NORTHGATE PLC (“Redde Northgate” or the “Group” or the “Company”)   Transaction in Own Shares   Redde Northgate plc (LSE:REDD) announces that on 03 January 2024 it purchased the following number of its own shares to be held in treasury:   Class of shares :  Ordinary shares of 50p (“shares”)

There are no items matching the current filter
There are no more items matching the current filter
Back to top